학술논문
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
Document Type
Article
Author
Ricciuti, Biagio; Elkrief, Arielle; Lin, Jessica; Zhang, Jianjun; Alessi, Joao V.; Lamberti, Giuseppe; Gandhi, Malini; Di Federico, Alessandro; Pecci, Federica; Wang, Xinan; Makarem, Maisam; Murilo Hidalgo Filho, Cassio; Gorria, Teresa; Pabon, Cindy; Lindsay, James; Pfaff, Kathleen L.; Welsh, Emma L.; Nishino, Mizuki; Sholl, Lynette M.; Rodig, Scott; Kilickap, Saadettin; Rietschel, Petra; McIntyre, Debra AG.; Pouliot, Jean-Francois; Altan, Mehmet; Gainor, Justin F.; Heymach, John V.; Schoenfeld, Adam J.; Awad, Mark M.
Source
In JTO Clinical and Research Reports April 2024
Subject
Language
ISSN
2666-3643